Spark Therapeutics Inc. | Mutual Funds
Mutual Funds that own Spark Therapeutics Inc.
Fidelity Select Biotechnology Portfolio
1,446,320
3.89%
0
0.97%
07/31/2018
Federated Kaufmann Fund
1,224,902
3.29%
-345,098
1.11%
06/29/2018
Hartford Mid Cap Fund
1,126,077
3.03%
41,182
0.52%
07/31/2018
T Rowe Price Health Sciences Fund
1,055,939
2.84%
-119,000
0.51%
06/30/2018
SPDR S&P Biotech ETF
937,520
2.52%
2,412
0.99%
09/06/2018
Fidelity Growth Company Fund
810,617
2.18%
-4,398
0.1%
07/31/2018
Vanguard Small Cap Index Fund
800,161
2.15%
11,039
0.05%
07/31/2018
Vanguard Total Stock Market Index Fund
798,661
2.15%
672
0.01%
07/31/2018
iShares Russell 2000 ETF
660,397
1.77%
-354
0.08%
09/06/2018
T Rowe Price New Horizons Fund
642,373
1.73%
-313,020
0.16%
06/30/2018
| Address |
3737 Market Street
Philadelphia Pennsylvania 19104
United States
|
|
Employees
|
- |
| Website |
http://www.sparktx.com |
| Updated |
07/08/2019 |
| Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. |
